Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

This study has been completed.
Sponsor:
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00312845
First received: April 7, 2006
Last updated: June 19, 2012
Last verified: June 2012
Results First Received: June 29, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Bortezomib + Rituximab
Drug: Rituximab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Bortezomib + Rituximab 1.6 mg/m^2 VELCADE for Injection administered weekly on Days 1, 8, 15, and 22 of a 35-day cycle in combination with 4 doses of 375 mg/m^2 rituximab once weekly on Days 1, 8, 15, and 22 of Cycle 1 and a single dose of 375 mg/m^2 rituximab on Day 1 of Cycles 2 through 5 (for a total of 8 doses of rituximab).
Rituximab 375 mg/m^2 rituximab once weekly on Days 1, 8, 15, and 22 of Cycle 1, and as a single dose of 375 mg/m^2 on Day 1 of Cycles 2 through 5 (for a total of 8 doses).

Participant Flow:   Overall Study
    Bortezomib + Rituximab   Rituximab
STARTED   336   340 
COMPLETED   237   245 
NOT COMPLETED   99   95 
Adverse Event                19                5 
Death                2                2 
Withdrawal by Subject                14                6 
Disease Progression                56                77 
Lost to Follow-up                2                0 
Other                6                5 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Bortezomib + Rituximab 1.6 mg/m^2 VELCADE for Injection administered weekly on Days 1, 8, 15, and 22 of a 35-day cycle in combination with 4 doses of 375 mg/m^2 rituximab once weekly on Days 1, 8, 15, and 22 of Cycle 1 and a single dose of 375 mg/m^2 rituximab on Day 1 of Cycles 2 through 5 (for a total of 8 doses of rituximab).
Rituximab 375 mg/m^2 rituximab once weekly on Days 1, 8, 15, and 22 of Cycle 1, and as a single dose of 375 mg/m^2 on Day 1 of Cycles 2 through 5 (for a total of 8 doses).
Total Total of all reporting groups

Baseline Measures
   Bortezomib + Rituximab   Rituximab   Total 
Overall Participants Analyzed 
[Units: Participants]
 336   340   676 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   243   242   485 
>=65 years   93   98   191 
Age 
[Units: Years]
Mean (Standard Deviation)
 56.8  (11.12)   57.3  (12)   57  (11.56) 
Gender 
[Units: Participants]
     
Female   164   203   367 
Male   172   137   309 
Region of Enrollment 
[Units: Participants]
     
United States   14   16   30 
Portugal   11   12   23 
Slovakia   7   8   15 
Greece   1   1   2 
Thailand   2   1   3 
Spain   9   5   14 
Ukraine   13   11   24 
Israel   7   7   14 
Russian Federation   52   55   107 
Italy   14   15   29 
India   17   24   41 
France   13   10   23 
Australia   5   3   8 
South Africa   2   2   4 
China   46   40   86 
Korea, Republic of   4   3   7 
Finland   1   2   3 
United Kingdom   9   10   19 
Hungary   3   6   9 
Czech Republic   18   17   35 
Mexico   9   8   17 
Canada   9   10   19 
Argentina   2   5   7 
Brazil   18   21   39 
Belgium   18   19   37 
Poland   24   21   45 
Romania   6   2   8 
Germany   0   3   3 
Sweden   2   3   5 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Progression Free Survival   [ Time Frame: Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months. ]
  Hide Outcome Measure 1

Measure Type Primary
Measure Title Progression Free Survival
Measure Description Progression free survival is defined as time from randomization to progressive disease or death due to any cause, whichever occurs first.
Time Frame Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months.  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intention to treat (ITT) population is defined as all patients randomized to the trial.

Reporting Groups
  Description
Bortezomib + Rituximab 1.6 mg/m^2 VELCADE for Injection administered weekly on Days 1, 8, 15, and 22 of a 35-day cycle in combination with 4 doses of 375 mg/m^2 rituximab once weekly on Days 1, 8, 15, and 22 of Cycle 1 and a single dose of 375 mg/m^2 rituximab on Day 1 of Cycles 2 through 5 (for a total of 8 doses of rituximab).
Rituximab 375 mg/m^2 rituximab once weekly on Days 1, 8, 15, and 22 of Cycle 1, and as a single dose of 375 mg/m^2 on Day 1 of Cycles 2 through 5 (for a total of 8 doses).

Measured Values
   Bortezomib + Rituximab   Rituximab 
Participants Analyzed 
[Units: Participants]
 336   340 
Progression Free Survival 
[Units: Days]
Median (95% Confidence Interval)
 389 
 (351 to 456) 
 334 
 (278 to 365) 


Statistical Analysis 1 for Progression Free Survival
Groups [1] All groups
Method [2] Log Rank
P Value [3] 0.039
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  No text entered.



2.  Secondary:   Overall Response Rate   [ Time Frame: Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months. ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information